住宅房产ETF-iShares REZ 深 沪
等待开盘 08-19 09:30:00 美东时间
81.44
-0.520
-0.63%
华盛通- 最 高82.1695
- 今 开82.02
- 成交量 2.38万股
- 最 低 81.44
- 昨 收 81.96
- 总市值 7.82亿
- 52周最高 89.6228
- 市盈率 静 --
- 换手率 0.25%
- 52周最低 72.7112
- 委 比 0.00%
- 总股本 960.00万
- 历史最高 93.1693
- 量 比 0.58
- 振 幅 0.89%
- 历史最低 27.343
- 每 手 1
- 风险率 2.44%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Somnigroup International's CorMedix to Acquire Melinta in $300M Deal, Expanding Infectious Disease Portfolio
CorMedix Inc. ("CorMedix") (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, and Melinta Therapeutics LLC ("Melinta"),
08-07 19:14
Nektar Therapeutics launches proposed public offering
Nektar Therapeutics (NASDAQ:NKTR) has commenced an underwritten public offering of shares of its common stock and pre-funded warrants to purchase shares of its common stock. NKTR -2.45% after hours to...
07-01 04:10
Nektar Therapeutics Announces Proposed Public Offering
SAN FRANCISCO, June 30, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of imm...
07-01 04:02
Nektar Therapeutics surge continues as stock up another 25%
Nektar Therapeutics (NASDAQ:NKTR), which closed Tuesday up ~156% after its lead asset, rezpegaldesleukin, met its main goal in a mid-stage trial for atopic dermatitis, also known as eczema, is up anot...
06-26 02:14
Why Is Nektar Therapeutics Stock Trading Higher On Wednesday?
Nektar's rezpegaldesleukin met key efficacy targets in a mid-stage eczema study, though analysts flagged safety and differentiation concerns.
06-26 01:42
美股异动 | Nektar Therapeutics(NKTR.US)大涨近30% 湿疹治疗药物临床研究取得超预期积极结果
周三，Nektar Therapeutics(NKTR.US)大涨近30%，报31.70美元。
06-25 22:25
创新药重磅消息! “T细胞黑马”Nektar(NKTR.US)湿疹疗效炸裂 股价单日暴涨150%
Nektar Therapeutics股价在美股盘中一度暴涨超180%，截至当日美股收盘收涨156%至24.450美元。
06-25 11:54
Nektar治疗公司湿疹药物试验结果乐观 股价翻倍
Nektar表示，其 2b 期研究在 393 名中重度特应性皮炎患者中开展。 核心要点 美国生物科技公司Nektar治疗（Nektar Therapeut...
06-25 00:07
Nektar Announces It Will Release Top-Line Data from 16-Week Induction Period In REZOLVE-AD Phase 2b Study of Rezpegaldesleukin On June 24, 2025
Nektar Therapeutics (NASDAQ:NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it will host an investor call and live webcast to review top-line data from
06-24 04:31
Mortgage Applications Jump 11% As Buyers Rush In Ahead Of Fed Decision
US homebuyers and refinancers took advantage of lower rates ahead of Fed's policy decision. Mortgage applications rose 11%, signaling housing market revival.
05-07 20:24
